Lysozyme: A paradigmatic molecule for the investigation of protein structure, function and misfolding

被引:70
作者
Merlini, G [1 ]
Bellotti, V [1 ]
机构
[1] Univ Pavia, Biotechnol Res Lab, Dept Biochem, Univ Hosp IRCCS Policlin San Matteo, I-27100 Pavia, Italy
关键词
lysozyme; amyloidosis; amyloid fibril;
D O I
10.1016/j.cccn.2005.03.022
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The term amyloidosis encompasses a wide group of conditions characterised by the tissue deposition of autologous proteins assembled in homogeneous regularly spaced antiparallel beta strands. The mechanism by which the different proteins gain a conformation, allowing monomers to bind to each other to form the regular amyloid fibril, is under intensive investigation. The discovery that human lysozyme, a protein thoroughly structurally and functionally characterised, can form amyloid fibrils has offered unique opportunities to unveil the molecular mechanisms involved in amyloid formation. Four amyloidogenic mutations have been identified and an apparently non-amyloidogenic polymorphism has been recently described. Results and conclusions: Lysozyme is well characterised for structure, function, folding dynamics and metabolism and comparative studies are becoming available that highlight pathogenic differences between the wild-type and the amyloidogenic variants. The chemical structure of lysozyme in natural amyloid fibrils was characterised in high detail in the early cases, but it is still lacking in the cases most recently discovered. Amyloidogenic lysozymes represent a prototypic molecule for new pharmaceutical approaches in which the formation of amyloid fibrils is abrogated through a stabilisation of the precursor. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:168 / 172
页数:5
相关论文
共 17 条
  • [1] Booth D R, 2000, Hum Mutat, V16, P180, DOI 10.1002/1098-1004(200008)16:2<180::AID-HUMU20>3.0.CO
  • [2] 2-#
  • [3] Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
    Booth, DR
    Sunde, M
    Bellotti, V
    Robinson, CV
    Hutchinson, WL
    Fraser, PE
    Hawkins, PN
    Dobson, CM
    Radford, SE
    Blake, CCF
    Pepys, MB
    [J]. NATURE, 1997, 385 (6619) : 787 - 793
  • [4] Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants
    Canet, D
    Sunde, M
    Last, AM
    Miranker, A
    Spencer, A
    Robinson, CV
    Dobson, CM
    [J]. BIOCHEMISTRY, 1999, 38 (20) : 6419 - 6427
  • [5] UNDERSTANDING HOW PROTEINS FOLD - THE LYSOZYME STORY SO FAR
    DOBSON, CM
    EVANS, PA
    RADFORD, SE
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1994, 19 (01) : 31 - 37
  • [6] A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
    Dumoulin, M
    Last, AM
    Desmyter, A
    Decanniere, K
    Canet, D
    Larsson, G
    Spencer, A
    Archer, DB
    Sasse, J
    Muyldermans, S
    Wyns, L
    Redfield, C
    Matagne, A
    Robinson, CV
    Dobson, CM
    [J]. NATURE, 2003, 424 (6950) : 783 - 788
  • [7] Single-domain antibody fragments with high conformational stability
    Dumoulin, M
    Conrath, K
    Van Meirhaeghe, A
    Meersman, F
    Heremans, K
    Frenken, LGJ
    Muyldermans, S
    Wyns, L
    Matagne, A
    [J]. PROTEIN SCIENCE, 2002, 11 (03) : 500 - 515
  • [8] Structural and folding dynamic properties of the T70N variant of human lysozyme*
    Esposito, G
    Garcia, J
    Mangione, P
    Giorgetti, S
    Corazza, A
    Viglino, P
    Chiti, F
    Andreola, A
    Dumy, P
    Booth, D
    Hawkins, PN
    Bellotti, V
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (28) : 25910 - 25918
  • [9] Klabunde T, 2000, NAT STRUCT BIOL, V7, P312
  • [10] Molecular mechanisms of amyloidosis
    Merlini, G
    Bellotti, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) : 583 - 596